Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.
A key chart suggests further gains in the chemical giant are possible, but be aware that it could explore lower levels of October again.
With 38 million Americans suffering from migraines, the FDA's approval of Eli Lilly's preventative migraine drug Emgality can help them get their lives back. We spoke with Christi Shaw, president, Lilly Bio-Medicines for all the details.
Valeant will become Bausch Health Cos. this summer. Here's what that could mean for the company as it continues to recover from controversy.
What was once a red and blue issue has now attracted a growing set of proponents from both sides of the aisle.
Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.